Galderma Laboratories, L.p.

Manufacturer Details

There are currently no manufacturer details available.

Galderma Laboratories, L.p. Drugs

Benzac

Benzac

• Start with clean, dry skin. Massage tube before use. Apply all over face, avoiding the eyes and mouth. Allow to dry for 5 minutes then rinse thoroughly and pat dry. Can be used 2-3 times per week.

• because excessive drying of the skin may occur, start with one application daily, then gradually increase to two times daily as needed or as directed by a doctor

• if bothersome dryness or peeling occurs, reduce application to once a day or every other day.
Benzac

Benzac

• wet face. Apply Acne Eliminating Cleanser and gently massage area for 1-2 minutes. Rinse thoroughly and pat dry. • because excessive drying of the skin may occur, start with one application daily, then gradually increase to two times daily as needed or as directed by a doctor. • if bothersome dryness or peeling occurs, reduce application to once a day or every other day. • if going outside, apply sunscreen after using this product. If irratation or sensitivity develops, stop use of both products and ask a doctor.
70% Isopropyl Rubbing A...

70% Isopropyl Rubbing Alcohol

For topical use only. EPIDUO FORTE gel is not for oral, ophthalmic, or intravaginal use.

Apply a thin layer of EPIDUO FORTE gel to affected areas of the face and/or trunk once daily after washing. Use a pea-sized amount for each area of the face (e.g., forehead, chin, each cheek). Avoid the eyes, lips and mucous membranes.
Dysport

Dysport

The potency Units of DYSPORT® are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of DYSPORT® cannot be compared to or converted into units of any other botulinum toxin products assessed with any other specific assay method [see Description (11)].

Reconstitution instructions are specific for each of the 300 Unit vial and the 500 Unit vial. These volumes yield concentrations specific for the use for each indication.

2.1 Cervical Dystonia

The recommended initial dose of DYSPORT® for the treatment of cervical dystonia is 500 Units given intramuscularly as a divided dose among affected muscles in patients with or without a history of prior treatment with botulinum toxin. (A description of the average DYSPORT® dose and percentage of total dose injected into specific muscles in the pivotal clinical trials can be found in Table 5 of Section 14.1, Clinical Studies – Cervical Dystonia.) Limiting the dose injected into the sternocleidomastoid muscle may reduce the occurrence of dysphagia. Clinical studies with DYSPORT® in cervical dystonia suggest that the peak effect occurs between two and four weeks after injection. Simultaneous EMG-guided application of DYSPORT® may be helpful in locating active muscles not identified by physical examination alone.

Dose Modification

Where dose modification is necessary for the treatment of cervical dystonia, uncontrolled open-label studies suggest that dose adjustment can be made in 250 Unit steps according to the individual patient's response, with re-treatment every 12 weeks or longer, as necessary, based on return of clinical symptoms. Uncontrolled open-label studies also suggest that the total dose administered in a single treatment should be between 250 Units and 1000 Units. Re-treatment, if needed, should not occur in intervals of less than 12 weeks. Doses above 1000 Units have not been systematically evaluated.

2.1.1 Special Populations

Adults and elderly

The starting dose of 500 Units recommended for cervical dystonia is applicable to adults of all ages [see Use in Specific Populations (8.5)].

Children

The safety and effectiveness of DYSPORT® in the treatment of cervical dystonia in pediatric patients less than 18 years of age has not been assessed [see Warnings and Precautions (5.2)].

2.1.2 Instructions for Preparation and Administration

DYSPORT® is supplied as a single-use vial. Each 500 Unit vial of DYSPORT® is to be reconstituted with 1 mL of 0.9% Sodium Chloride Injection USP (without preservative) to yield a solution of 500 Units per mL. Each 300 Unit vial of DYSPORT® is to be reconstituted with 0.6 mL of 0.9% Sodium Chloride Injection USP (without preservative) to yield a solution equivalent to 250 Units per 0.5 mL.

Using an appropriately sized sterile syringe, needle and aseptic technique, draw up 1.0 mL or 0.6 mL of sterile, 0.9% Sodium Chloride Injection USP (without preservative) for 500 and 300 Unit vials, respectively. Insert the needle into the DYSPORT® vial. The partial vacuum will begin to pull the saline into the vial. Any remaining required saline should be expressed into the vial manually. Do not use the vial if no vacuum is observed. Swirl gently to dissolve. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Reconstituted DYSPORT® should be a clear, colorless solution, free of particulate matter, otherwise it should not be injected.

Expel any air bubbles in the syringe barrel. Remove the needle used to reconstitute the product and attach an appropriately sized new sterile needle.

Once reconstituted, DYSPORT® should be stored in a refrigerator at 2–8°C (36–46°F) protected from light and used within 24 hours. Do not freeze reconstituted DYSPORT®. Discard the vial and needle in accordance with local regulations.

2.2 Glabellar Lines

The dose of DYSPORT® for the treatment of glabellar lines is a total of 50 Units given intramuscularly in five equal aliquots of 10 Units each to achieve clinical effect (see Figure 1).

2.2.1 Special Populations

Adults

A total dose of 50 Units of DYSPORT®, in five equal aliquots, should be administered to achieve clinical effect.

The clinical effect of DYSPORT® may last up to four months. Repeat dose clinical studies demonstrated continued efficacy with up to four repeated administrations. It should be administered no more frequently than every three months. When used for re-treatment, DYSPORT® should be reconstituted and injected using the same techniques as the initial treatment.

Children

DYSPORT® for glabellar lines is not recommended for use in pediatric patients less than 18 years of age [see Warnings and Precautions (5.2)].

2.2.2 Instructions for Preparation and Administration

DYSPORT® is supplied as a single-use vial. Each 300 Unit vial of DYSPORT® is to be reconstituted with 2.5 mL of 0.9% Sodium Chloride Injection USP (without preservative) prior to injection. The concentration of the resulting solution will be 10 Units per 0.08 mL to be delivered in five equally divided aliquots of 0.08 mL each. DYSPORT® may also be reconstituted with 1.5 mL of 0.9% Sodium Chloride Injection USP (without preservative) for a solution of 10 Units per 0.05 mL to be delivered in five equally divided aliquots of 0.05 mL each.

Using an appropriately sized sterile syringe, needle and aseptic technique, draw up 2.5 mL or 1.5 mL of 0.9% Sodium Chloride Injection USP (without preservative). Insert the needle into the DYSPORT® vial. The partial vacuum will begin to pull the saline into the vial. Any remaining required saline should be expressed into the vial manually. Do not use the vial if no vacuum is observed. Swirl gently to dissolve. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Reconstituted DYSPORT® should be a clear, colorless solution, free of particulate matter otherwise it should not be injected.

Draw a single patient dose of DYSPORT® into a sterile syringe. Expel any air bubbles in the syringe barrel. Remove the needle used to reconstitute the product and attach a 30 gauge needle.

Once reconstituted, DYSPORT® should be stored in a refrigerator at 2–8°C (36–46°F) protected from light and used within 24 hours. Do not freeze reconstituted DYSPORT®. Discard the vial and needle in accordance with local regulations.

2.2.3 Injection Technique

Glabellar facial lines arise from the activity of the lateral corrugator and vertical procerus muscles. These can be readily identified by palpating the tensed muscle mass while having the patient frown. The corrugator depresses the skin creating a "furrowed" vertical line surrounded by tensed muscle (i.e., frown lines). The location, size, and use of the muscles vary markedly among individuals. Physicians administering DYSPORT® must understand the relevant neuromuscular and/or orbital anatomy of the area involved and any alterations to the anatomy due to prior surgical procedures.

Risk of ptosis can be mitigated by careful examination of the upper lid for separation or weakness of the levator palpebrae muscle (true ptosis), identification of lash ptosis, and evaluation of the range of lid excursion while manually depressing the frontalis to assess compensation.

In order to reduce the complication of ptosis, the following steps should be taken:
Avoid injection near the levator palpebrae superioris, particularly in patients with larger brow depressor complexes. Medial corrugator injections should be placed at least 1 centimeter above the bony supraorbital ridge. Ensure the injected volume/dose is accurate and where feasible kept to a minimum. Do not inject toxin closer than 1 centimeter above the central eyebrow.
To inject DYSPORT®, advance the needle through the skin into the underlying muscle while applying finger pressure on the superior medial orbital rim. Inject patients with a total of 50 Units in five equally divided aliquots. Using a 30 gauge needle, inject 10 Units of DYSPORT® into each of five sites, two in each corrugator muscle, and one in the procerus muscle (see Figure 1).

Figure 1
Benzac – Complete...

Benzac – Complete Acne Solution Regimen

• Wet face. Pump a small amount of cleanser onto wet palms. Gently massage the cleanser all over your face for about 20-30 seconds, avoiding the eye area. Rinse thoroughly, then pat dry.

• Because excesssive drying of the skin may occur, start with one application daily, then gradually increase to two times daily as needed or as directed by a doctor

• If bothersome dryness or peeling occurs, reduce application to once a day or every other day.

• Clean the skin thoroughly before applying this product

• Cover the entire affected area with a thin layer once or twice daily

• Because excesssive drying of the skin may occur, start with one application daily, then gradually increase to two times daily as needed or as directed by a doctor

• If bothersome dryness or peeling occurs, reduce application to once a day or every other day.

• Clean the skin thoroughly before applying this product

• Cover the entire affected area with a thin layer once or twice daily

• Because excesssive drying of the skin may occur, start with one application daily, then gradually increase to two times daily as needed or as directed by a doctor

• If bothersome dryness or peeling occurs, reduce application to once a day or every other day.
Benzac

Benzac

• clean the skin thoroughly before applying this product

• cover the entire affected area with a thin layer once or twice daily

• because drying of the skin may occur, start with one application daily, then gradually increase to two times daily as needed or as directed by a doctor

• if bothersome dryness or peeling occurs, reduce application to once a day or every other day.»
Benzac

Benzac

Drug Facts (continued)

Directions

• wet face. Pump a small amount of cleanser onto wet palms. Gently massage the cleanser all over your face for about 20-30 seconsd, avoiding the eye area. Rinse thoroughly, then pat dry.

• because excesssive drying of the skin may occur, start with one application daily, then gradually increase to two times daily as needed or as directed by a doctor

• if bothersome dryness or peeling occurs, reduce application to once a day or every other day.
Benzac

Benzac

• clean the skin thoroughly before applying this product

• cover the entire affected area with a thin layer once or twice daily

• because excesssive drying of the skin may occur, start with one application daily, then gradually increase to two times daily as needed or as directed by a doctor

• if bothersome dryness or peeling occurs, reduce application to once a day or every other day.»
Benzac

Benzac

• clean the skin thoroughly before applying this product

• cover the entire affected area with a thin layer once or twice daily

• because excesssive drying of the skin may occur, start with one application daily, then gradually increase to two times daily as needed or as directed by a doctor

• if bothersome dryness or peeling occurs, reduce application to once a day or every other day.»
Differin

Differin

DIFFERIN® Cream should be applied to affected areas of the skin, once daily at nighttime. A thin film of the cream should be applied to the skin areas where acne lesions appear, using enough to cover the entire affected areas lightly. A mild transitory sensation of warmth or slight stinging may occur shortly after the application of DIFFERIN® Cream.
Capex

Capex

The pharmacist must empty the contents of the enclosed capsule into the shampoo base prior to dispensing to the patient. This product should be shaken well prior to use. No more than approximately one (1) ounce of the medicated shampoo should be applied to the scalp area once daily, worked into a lather and allowed to remain on the scalp for approximately 5 minutes. The hair and scalp should then be rinsed thoroughly with water.
Metrocream

Metrocream

Apply and rub in a thin layer of METROCREAM® (metronidazole topical cream) Topical Cream twice daily, morning and evening, to entire affected areas after washing.

Areas to be treated should be washed with a mild cleanser before application. Patients may use cosmetics after application of METROCREAM® Topical Cream.
Metrolotion

Metrolotion

Apply a thin layer to entire affected areas after washing. Use morning and evening or as directed by physician. Avoid application close to the eyes.

Patients may use cosmetics after waiting for the MetroLotion® Topical Lotion to dry (not less than 5 minutes).
Equaline Hair Regrowth ...

Equaline Hair Regrowth Treatment For Women

Drug Facts (continued)

Directions

• wet face. Pump a small amount of cleanser onto wet palms. Gently massage the cleanser all over your face for about 20-30 seconsd, avoiding the eye area. Rinse thoroughly, then pat dry.

• because excesssive drying of the skin may occur, start with one application daily, then gradually increase to two times daily as needed or as directed by a doctor

• if bothersome dryness or peeling occurs, reduce application to once a day or every other day.
Gold Bond Foot Extra St...

Gold Bond Foot Extra Strength

DesOwen® Cream or Lotion should be applied to the affected areas as a thin film two or three times daily depending on the severity of the condition. SHAKE LOTION WELL BEFORE USING.

As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.

DesOwen® Cream and Lotion should not be used with occlusive dressings.
Cetaphil Daily Facial M...

Cetaphil Daily Facial Moisturizer Spf 50

Apply liberally and evenly to face and neck before sun exposure. Reapply every 2 hours and after towel drying, swimming or perspiring.
Cetaphil Gentle Cleansi...

Cetaphil Gentle Cleansing Antibacterial Bar

Apply to skin while bathing or washing. Rinse and repeat.
Cetaphil Dermacontrol S...

Cetaphil Dermacontrol Spf 30

• Apply liberally 15 minutes before sun exposure.• Use a water resistant sunscreen if swimming or sweating.• Reapply at least every 2 hours.• Children under 6 months: Ask a doctor.

Sun Protection Measures. Spending time in the sun increases your risk of cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a Broad Spectrum SPF value of 15 or higher and other sun protection measures including: • Limit time in the sun, especially from 10 a.m. - 2 p.m. • Wear long-sleeved shirts, pants, hats, and sunglasses.
Metrogel

Metrogel

Apply and rub in a thin film of METROGEL once daily to affected area(s).

A gentle cleanser should be used before the application of METROGEL.

Cosmetics may be applied after the application of METROGEL.

Not for oral, ophthalmic or intravaginal use.
Epiduo

Epiduo

For topical use only; EPIDUO gel is not for oral, ophthalmic, or intravaginal use.

Apply a thin film of EPIDUO gel to affected areas of the face and/or trunk once daily after washing. Use a pea-sized amount for each area of the face (e.g., forehead, chin, each cheek). Avoid the eyes, lips and mucous membranes.
Flu-cold

Flu-cold

Apply to the affected areas of the face once daily. Use a pea-size amount for each area of the face (forehead, chin, nose, each cheek) that is affected. Spread as a thin layer, avoiding the eyes and lips. SOOLANTRA cream is not for oral, ophthalmic, or intravaginal use.
Oracea

Oracea

2.1 General Dosing Information

One ORACEA Capsule (40 mg) should be taken once daily in the morning on an empty stomach, preferably at least one hour prior to or two hours after meals.

Administration of adequate amounts of fluid along with the capsules is recommended to wash down the capsule to reduce the risk of esophageal irritation and ulceration [see Adverse Reactions (6)].

2.2 Important Considerations for Dosing Regimen

The dosage of ORACEA differs from that of doxycycline used to treat infections. Exceeding the recommended dosage may result in an increased incidence of side effects including the development of resistant organisms.
Penaqua Sol-g

Penaqua Sol-g

Apply VECTICAL Ointment to affected areas twice daily, morning and evening. The maximum weekly dose should not exceed 200 grams.

VECTICAL Ointment is not for oral, ophthalmic or intravaginal use.
Mirvaso

Mirvaso

Apply a pea-sized amount once daily to each of the five areas of the face: central forehead, chin, nose, each cheek. MIRVASO topical gel should be applied smoothly and evenly as a thin layer across the entire face avoiding the eyes and lips.

Wash hands after applying MIRVASO topical gel.

MIRVASO topical gel is not for oral, ophthalmic, or intravaginal use.
Clobex

Clobex

CLOBEX Shampoo, 0.05% is for topical use only, and not for ophthalmic, oral or intravaginal use.CLOBEX Shampoo, 0.05%, should be applied onto dry (not wet) scalp once a day in a thin film to the affected areas only, and left in place for 15 minutes before lathering and rinsing. The total dosage should not exceed 50 g (50 mL or 1.75 fl. oz.) per week. Move the hair away from the scalp so that one of the affected areas is exposed. Position the bottle over the lesion. Apply a small amount of the shampoo directly onto the lesion, letting the product naturally flow from the bottle (gently squeeze the bottle), avoiding any contact of the product with the facial skin, eyes or lips. In case of contact, rinse thoroughly with water. Spread the product so that the entire lesion is covered with a thin uniform film. Massage gently into the lesion and repeat for additional lesion(s). Wash your hands after applying CLOBEX Shampoo, 0.05%.Leave the shampoo in place for 15 minutes, then add water, lather and rinse thoroughly all parts of the scalp and body that came in contact with the shampoo (e.g., hands, face, neck and shoulders). Avoid contact with eyes and lips. Minimize contact to non-affected areas of the body. Although no additional shampoo is necessary to cleanse your hair, you may use a non-medicated shampoo if desired.Treatment should be limited to 4 consecutive weeks. As with other corticosteroids, therapy should be discontinued when control is achieved. If complete disease control is not achieved after 4 weeks of treatment with CLOBEX Shampoo, 0.05%, treatment with a less potent topical steroid may be substituted. If no improvement is seen within 4 weeks, reassessment of the diagnosis may be necessary.CLOBEX Shampoo, 0.05%, should not be used with occlusive dressings (shower cap or bathing cap) unless directed by a physician.
Clindagel

Clindagel

Apply a thin film of Clindagel® once daily to the skin where acne lesions appear. Use enough to cover the entire affected area lightly.

Keep container tightly closed.
Differin

Differin

Apply a thin film of DIFFERIN Lotion to the entire face and other affected areas of the skin once daily, after washing gently with a mild soapless cleanser. Dispense a nickel size amount of DIFFERIN Lotion (3-4 actuations of the pump) to cover the entire face. Avoid application to the areas of skin around eyes, lips and mucous membranes. DIFFERIN Lotion is for topical use only and not for oral, ophthalmic, or intravaginal use.
Differin

Differin

Apply a thin film of DIFFERIN Gel, 0.3% to the entire face and any other affected areas of the skin once daily in the evening, after washing gently with a non-medicated soap. Avoid application to the areas of skin around eyes, lips, and mucous membranes. A mild transitory sensation of warmth or slight stinging may occur shortly after the application of DIFFERIN Gel, 0.3%. Patients should be instructed to minimize sun exposure. Patients may be instructed to use moisturizers for relief of dry skin or irritation.

If therapeutic results are not noticed after 12 weeks of treatment, therapy should be re-evaluated.

For topical use only. Not for ophthalmic, oral or intravaginal use.
Tri-luma

Tri-luma

Apply a thin film of TRI-LUMA Cream to the effected area once daily, at least 30 minutes before bedtime.

Gently wash the face and neck with a mild cleanser. Rinse and pat the skin dry. Apply TRI-LUMA Cream to the hyperpigmented areas of melasma including about 1/2 inch of normal appearing skin surrounding each lesion. Rub lightly and uniformly into the skin.

Therapy should be discontinued when control is achieved.

During the day, use a sunscreen of SPF 30, and wear protective clothing. Avoid sunlight exposure. Patients may use moisturizers and/or cosmetics during the day.

TRI-LUMA Cream is for topical use only. It is not for oral, ophthalmic, or intravaginal use.
Clobex

Clobex

CLOBEX® Spray, 0.05% is for topical use only, and not for ophthalmic, oral or intravaginal use.

CLOBEX® Spray, 0.05% should be sprayed directly onto the affected skin areas twice daily and rubbed in gently and completely.

The total dosage should not exceed 50 g (59 mL or 2 fluid ounces) per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. Do not use more than 26 sprays per application or 52 sprays per day.

CLOBEX® Spray, 0.05% contains a topical corticosteroid; therefore treatment should be limited to 4 weeks. Therapy should be discontinued when control has been achieved. Treatment beyond 2 weeks should be limited to localized lesions of moderate to severe plaque psoriasis that have not sufficiently improved after the initial 2 weeks of treatment with CLOBEX® Spray, 0.05%. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary. Before prescribing for more than 2 weeks, any additional benefits of extending treatment to 4 weeks should be weighed against the risk of HPA axis suppression.

Use in pediatric patients younger than 18 years is not recommended because of the potential for HPA axis suppression see [Use in Specific Populations (8.4)].

Unless directed by physician, CLOBEX® Spray, 0.05% should not be used with occlusive dressings.
Pliaglis

Pliaglis

2.1 General Dosing Information

PLIAGLIS Cream should only be applied to intact skin.

For use in adults only.

• For superficial dermatological procedures such as dermal filler injection, non-ablative laser facial resurfacing, or pulsed-dye laser therapy, apply PLIAGLIS Cream to intact skin for 20-30 minutes prior to the procedure. See Table 1 for instructions on the amount to apply.

• For superficial dermatological procedures such as laser-assisted tattoo removal, apply PLIAGLIS Cream to intact skin for 60 minutes prior to the procedure. See Table 1 for instructions on the amount to apply.

The dose of PLIAGLIS Cream that provides effective local dermal analgesia depends on the duration of the application. Although not specifically studied, a shorter duration of application may result in a less complete dermal analgesia or a shorter duration of adequate dermal analgesia.

2.2 Dosage Information

Determine the amount of drug to apply.

The amount (length) of PLIAGLIS Cream that should be dispensed is determined by the size of the area to be treated (see Table 1).

(a) Using the ruler supplied on the carton, squeeze out and measure the amount of PLIAGLIS Cream that approximates the amount required to achieve proper coverage.

(b) Spread PLIAGLIS Cream evenly and thinly (approximately 1 mm or the thickness of a dime) across the treatment area using a flat-surfaced tool such as a metal spatula or tongue depressor.

(c) After waiting the required application time, remove the PLIAGLIS Cream by grasping a free-edge with your fingers and pulling it away from the skin.

Table 1. Amount of PLIAGLIS Cream According to Treatment Site Surface Area

2.3 Important Dosage and Administration Instructions

Important Dosage and Administration instructions include:
Remove PLIAGLIS Cream if skin irritation or a burning sensation occurs during application. In order to minimize the risk of systemic toxicity, do not exceed the recommended amount of drug to apply or the duration of the application [see Overdosage (10)]. Avoid eye contact with PLIAGLIS Cream. Wash hands after handling PLIAGLIS Cream. Upon removal from the treatment site, discard the used PLIAGLIS Cream in a location that is out of the reach of children and pets. Access to PLIAGLIS Cream by children or pets should be prevented during usage and storage of the product [see Warnings and Precautions (5.2)].
Clobex

Clobex

CLOBEX Lotion, 0.05% is for topical use only, and not for ophthalmic, oral or intravaginal use.CLOBEX Lotion, 0.05% should be applied to the affected skin areas twice daily and rubbed in gently and completely.The total dosage should not exceed 50 g (50 mL or 1.75 fl. oz.) per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. CLOBEX Lotion, 0.05% contains a topical corticosteroid; therefore treatment should be limited to 2 consecutive weeks for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses and up to 2 additional weeks in localized lesions (less than 10% body surface area) of moderate to severe plaque psoriasis that have not sufficiently improved after the initial 2 weeks of treatment with CLOBEX Lotion, 0.05%. Unless directed by physician, CLOBEX Lotion, 0.05% should not be used with occlusive dressings.
Differin

Differin

DIFFERIN Gel should be applied once a day to affected areas after washing in the evening before retiring. A thin film of the gel should be applied, avoiding eyes, lips, and mucous membranes.

During the early weeks of therapy, an apparent exacerbation of acne may occur. This is due to the action of the medication on previously unseen lesions and should not be considered a reason to discontinue therapy. Therapeutic results should be noticed after eight to twelve weeks of treatment.
Rosanil

Rosanil

Wash affected areas once or twice daily, or as directed by your physician. Avoid contact with eyes or mucous membranes. Wet skin and liberally apply to areas to be cleansed, massage gently into skin for 10–20 seconds working into a full lather, rinse thoroughly and pat dry. If drying occurs, it may be controlled by rinsing cleanser off sooner or using less often.

Galderma Laboratories, L.p.

Manufacturer Details

Share This Page

Galderma Laboratories, L.p. Drugs